Exacerbation frequency · children with bronchiectasis
Macrolides may leads to lower exacerbation frequency compared with placebo (low certainty).
1 finding from 1 review
Hospitalisation (any cause) · children with bronchiectasis
Macrolides showed no clear difference in hospitalisation: all‐cause compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · children with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · children with bronchiectasis
1 finding from 1 review
Quality of life not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations ‐ not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalisation ‐ not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalisation (any cause) · adults with bronchiectasis
Macrolides showed no clear difference in hospitalisation: all cause compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · children with bronchiectasis
1 finding from 1 review
Quality of life ‐ not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · adults with bronchiectasis
1 finding from 1 review
Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · adults with bronchiectasis
1 finding from 1 review
Quality of life: change · adults with bronchiectasis
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults with bronchiectasis
Macrolides showed no clear difference in ≥ 1 exacerbation compared with no intervention (moderate certainty).
1 finding from 1 review
Hospitalisation ‐ not reported · adults with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · adults with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID
It is very uncertain whether regimens containing macrolides (azithromycin) changes clinical cure according to criteria established by study authors… compared with regimens containing tetracycline (doxycycline) (very low certainty).
2 findings from 1 review
RR 1.18 [0.89, 1.55]
Studies not reported
Very low
RR 1.35 [1.1, 1.67]
Studies not reported
Moderate
Clinical cure according to criteria established by study authors Severe PID · women with PID
Regimens containing macrolides (azithromycin) showed no clear difference in clinical cure according to criteria established by study authors… compared with regimens containing tetracycline (doxycycline) (low certainty).
1 finding from 1 review
RR 1 [0.96, 1.05]
Studies not reported
Low